Search

Your search keyword '"Spillane, Andrew J."' showing total 499 results

Search Constraints

Start Over You searched for: Author "Spillane, Andrew J." Remove constraint Author: "Spillane, Andrew J."
499 results on '"Spillane, Andrew J."'

Search Results

1. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

3. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

5. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort

6. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

8. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

9. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach

10. Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study

11. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

12. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

13. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

14. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

15. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

16. Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting

18. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

20. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

22. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

23. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

24. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

28. Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study

30. Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma

31. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

32. The complexities of establishing a surgical multi‐centre registry in Australia: challenges, and possible solution.

35. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

36. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

37. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

39. ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma

45. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity

47. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study

48. Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma

49. Abstract 81: The association between melanoma liver metastases (mets) and the systemic anti-tumor immune profile

50. Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Catalog

Books, media, physical & digital resources